223 related articles for article (PubMed ID: 34094680)
1. High concordance of mutation patterns in 10 common mutated genes between tumor tissue and cell-free DNA in metastatic colorectal cancer.
Lan YT; Chang SC; Lin PC; Lin CH; Liang WY; Chen WS; Jiang JK; Yang SH; Lin JK
Am J Cancer Res; 2021; 11(5):2228-2237. PubMed ID: 34094680
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer.
Kung CY; Fang WL; Hung YP; Huang KH; Chen MH; Chao Y; Lin SC; Li AF; Lo SS; Wu CW
Aging (Albany NY); 2023 Feb; 15(3):777-790. PubMed ID: 36779847
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer.
Rodríguez-Casanova A; Bao-Caamano A; Lago-Lestón RM; Brozos-Vázquez E; Costa-Fraga N; Ferreirós-Vidal I; Abdulkader I; Vidal-Insua Y; Rivera FV; Candamio Folgar S; López-López R; Muinelo-Romay L; Diaz-Lagares A
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640513
[TBL] [Abstract][Full Text] [Related]
5. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
6. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
[TBL] [Abstract][Full Text] [Related]
8. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
9. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
Bádon ES; Mokánszki A; Mónus A; András C; Méhes G
Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518
[TBL] [Abstract][Full Text] [Related]
10. Detection of KRAS mutations in plasma cell-free DNA of colorectal cancer patients and comparison with cancer panel data for tissue samples of the same cancers.
Min S; Shin S; Chung YJ
Genomics Inform; 2019 Dec; 17(4):e42. PubMed ID: 31896242
[TBL] [Abstract][Full Text] [Related]
11.
Paliogiannis P; Cossu A; Tanda F; Palmieri G; Palomba G
Oncol Lett; 2014 Oct; 8(4):1422-1426. PubMed ID: 25202344
[No Abstract] [Full Text] [Related]
12. Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer.
Chan RH; Lin PC; Chen SH; Lin SC; Chen PC; Lin BW; Shen MR; Yeh YM
Front Oncol; 2021; 11():589673. PubMed ID: 33816227
[TBL] [Abstract][Full Text] [Related]
13. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
14. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
15. Identification of an optimal mutant allele frequency to detect activating
Caughey BA; Umemoto K; Green MF; Ikeda M; Lowe ME; Ueno M; Niedzwiecki D; Taniguchi H; Walden DJ; Komatsu Y; D'Anna R; Esaki T; Denda T; Datto MB; Bando H; Bekaii-Saab T; Yoshino T; Strickler JH; Nakamura Y
J Gastrointest Oncol; 2023 Oct; 14(5):2083-2096. PubMed ID: 37969845
[TBL] [Abstract][Full Text] [Related]
16. Fractionated small cell-free DNA increases possibility to detect cancer-related gene mutations in advanced colorectal cancer.
Ishida Y; Takano S; Maekawa S; Yamaguchi T; Yoshida T; Kobayashi S; Iwamoto F; Kuno T; Hayakawa H; Matsuda S; Fukasawa M; Shindo H; Inoue T; Nakayama Y; Ichikawa D; Sato T; Enomoto N
JGH Open; 2020 Oct; 4(5):978-986. PubMed ID: 33102773
[TBL] [Abstract][Full Text] [Related]
17. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
[TBL] [Abstract][Full Text] [Related]
18. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
[TBL] [Abstract][Full Text] [Related]
19. Differences in DNA damage repair gene mutations between left- and right-sided colorectal cancer.
Huang W; Li W; Xu N; Li H; Zhang Z; Zhang X; He T; Yao J; Xu M; He Q; Guo L; Zhang S
Cancer Med; 2023 May; 12(9):10187-10198. PubMed ID: 37096801
[TBL] [Abstract][Full Text] [Related]
20. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer.
Lavacchi D; Fancelli S; Roviello G; Castiglione F; Caliman E; Rossi G; Venturini J; Pellegrini E; Brugia M; Vannini A; Bartoli C; Cianchi F; Pillozzi S; Antonuzzo L
Front Oncol; 2022; 12():1055019. PubMed ID: 36523988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
